Walmart Pays $50M Over Opioid Prescription Fills

Walmart will pay $50 million to settle federal allegations that its pharmacies repeatedly filled thousands of invalid prescriptions for controlled substances, including opioids. This agreement was announced by the Justice Department and the Drug Enforcement Administration on Friday, August 29, 2026. The government's complaint, filed in December 2020, alleged that Walmart's compliance staff and pharmacists knowingly dispensed prescriptions that did not meet the Controlled Substances Act requirements.

Despite internal "refusal-to-fill" reports flagging suspect orders from potentially illegal prescribers and highlighting risky drug combinations, the company allegedly prioritized sales over reviewing these critical reports. Associate Attorney General Stanley Woodward emphasized that corporate profits cannot justify fueling the opioid epidemic. The settlement includes a DEA memorandum of agreement requiring a dedicated hotline for employees and patients, detailed monitoring of pharmacy dispensing patterns, and a process to vet suspected illegal prescribers. While the settlement resolves these allegations, it does not include a finding of liability for Walmart, which has previously paid significant sums to resolve similar claims from states and other entities.